CHRNA7 Antikörper (N-Term)
Kurzübersicht für CHRNA7 Antikörper (N-Term) (ABIN926024)
Target
Alle CHRNA7 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- N-Term
-
Kreuzreaktivität
- Hund, Maus, Ratte (Rattus), Rind (Kuh), Huhn
-
Immunogen
- CHRNA7 antibody was raised in rabbit using the N terminal of CHRNA7 as the immunogen
-
-
-
-
Applikationshinweise
-
WB: 2.5 µg/mL
Optimal conditions should be determined by the investigator. -
Kommentare
-
CHRNA7 Blocking Peptide, , is also available for use as a blocking control in assays to test for specificity of this CHRNA7 antibody
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Lyophilized
-
Konzentration
- Lot specific
-
Buffer
- Lyophilized powder. Add 100 µL of distilled water. Final antibody concentration is 1 mg/mL in PBS buffer.
-
Handhabung
- Avoid repeated freeze/thaw cycles.
-
Lagerung
- 4 °C/-20 °C
-
Informationen zur Lagerung
- Store at 4 °C, following reconstitution, aliquot and store at -20 °C.
-
-
- CHRNA7 (Cholinergic Receptor, Nicotinic, alpha 7 (Neuronal) (CHRNA7))
-
Andere Bezeichnung
- CHRNA7
-
Hintergrund
- The nicotinic acetylcholine receptors (nAChRs) are members of a superfamily of ligand-gated ion channels that mediate fast signal transmission at synapses. The nAChRs are thought to be hetero-pentamers composed of homologous subunits. The proposed structure for each subunit is a conserved N-terminal extracellular domain followed by three conserved transmembrane domains, a variable cytoplasmic loop, a fourth conserved transmembrane domain, and a short C-terminal extracellular region. Synonyms: Polyclonal CHRNA7 antibody, Anti-CHRNA7 antibody, cholinergic receptor, nicotinic, alpha 7 antibody.
-
Pathways
- Synaptic Membrane
Target
-